Human medicines European public assessment report (EPAR): Cyltezo, adalimumab, Hidradenitis Suppurativa,Arthritis, Psoriatic,Psoriasis,Crohn Disease,Arthritis, Juvenile Rheumatoid,Uveitis,Arthritis, Rheumatoid,Colitis, Ulcerative,Spondylitis, Ankylosing, Date of authorisation: 10/11/2017, Revision: 2, Status: Withdrawn

2019 ◽  
Author(s):  
Sign in / Sign up

Export Citation Format

Share Document